Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00931255 · ClinicalTrials.gov registry record · Phase 4

Tacrolimus to Sirolimus Conversion for Delayed Graft Function

A Phase 4 study, sponsored by University of Maryland, Baltimore.

Terminated
Registry status
Phase 4
Development phase
32
Enrollment target

NCT00931255: Clinical Trial Phase 4 study, sponsored by University of Maryland, Baltimore.

NCT00931255 is a Phase 4 study that was terminated before completion, run by University of Maryland, Baltimore. The registered enrollment target is 32 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00931255, a Phase 4 study, was terminated before completion, sponsored by University of Maryland, Baltimore.

TERMINATED
Registry status
Phase 4
Development phase
32 participants
Enrollment target

Study Summary

The objective of this study is to evaluate the safety and efficacy of conversion from tacrolimus to sirolimus early after kidney transplantation in patients with delayed graft function (DGF)and slow graft function (SGF) in improving graft function and delaying chronic allograft nephropathy. The investigators hypothesize that conversion from tacrolimus to sirolimus in renal transplant recipients with DGF/SGF in early months after surgery will improve graft function and decrease the progression of graft fibrosis.

Interventions

  • DRUG Sirolimus
  • DRUG Tacrolimus

Trial Details

FieldValue
Enrollment Target 32 participants
Start Date 2009-04
Est. Completion 2014-07
Phase Phase 4
University of Maryland, Baltimore

560 total trials

Why NCT00931255 stopped before completion

NCT00931255 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (94% lower).

The record links to 0 conditions, and to 2 interventions - of which Sirolimus is the first listed.

NCT00931255 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00931255 about?

NCT00931255 is a clinical study titled "Tacrolimus to Sirolimus Conversion for Delayed Graft Function". The objective of this study is to evaluate the safety and efficacy of conversion from tacrolimus to sirolimus early after kidney transplantation in patients with delayed graft function (DGF)and slow graft function (SGF) in improving graft function and delaying chronic allograft nephropathy. The inve...

What is the current status of trial NCT00931255?

This trial is currently terminated. It is a Phase 4 study. The enrollment target is 32 participants. The study started on 2009-04. Estimated completion is 2014-07.

What interventions are being tested in trial NCT00931255?

The interventions under investigation include: Sirolimus (DRUG), Tacrolimus (DRUG).

Who is sponsoring clinical trial NCT00931255?

This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00931255's enrollment target sits among peer trials

32 1534th of 2000 higher than 457 of 2,000 other Phase 4 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02445781 · 32 participants · Early Phase 1

    Differing Levels of Hypoglycemia

  • NCT02792270 · 32 participants · NA

    Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT

  • NCT03068910 · 32 participants · Early Phase 1

    Hyperandrogenemia and Altered Day-night LH Pulse Patterns

  • NCT03208868 · 32 participants · NA

    Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00931255, the US trial registry maintained by the National Library of Medicine. NCT00931255 (small enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.